Join Medicilon at BioSeed 2023——The Early-Stage Life Sciences Investment Event

We are very pleased to announce that Medicilon will participate in the BioSeed 2023. It kicks off on Monday 23 January in Venues County Hall, London.  
Medicilon European team team will be present throughout the event. We welcome you to join us at the forum! Please stop by our booth and chat how our services and capabilities would support your research needs and expedite your drug discovery and development programs.

About BioSeed 2023

BioSeed, which is organised by OBN, is a fast-paced, one-day pitching event where innovative early-stage Life Sciences companies seeking Seed funding, showcase to and meet with an extensive audience of active life sciences investors.
Key features of the event include:
❖40 x 5-minute company presentations from early-stage life sciences R&D companies seeking seed stage funding
❖Inspirational keynote presentations and an investor workshop
❖Private pre-scheduled partnering meetings in-person on 23 January, and virtually on 24 January (powered by PartneringONE)
❖Plenty of networking opportunities throughout the day, along with a Networking Drinks Reception at the end of day one.

Medicilon Drug Discovery Services

Medicilon drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!

Medicilon Chemistry Research Services

With the rapid development of the global pharmaceutical market and the division of labor in the pharmaceutical industry, the chain is becoming more and more refined, making specialized outsourcing in the pharmaceutical industry an important strategic choice for pharmaceutical companies. In the early stages of new drug development, FTE (Full-time equivalent) is often used by drug discovery companies to synthesize the required structural fragments and/or potential candidate compounds to accelerate the drug screening process.Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and customers can cooperate with us through the FFS (Fee for Service) or FTE (Full-time Equivalent Service) models.

PROTAC Drug Discovery Technology Platform

Medicinal Chemistry has established the PROTAC drug discovery technology platform, which summarizes the current popular target protein ligands, establishes an extensive library of high-affinity small molecules and small molecule fragments of popular target proteins (TPSM), an extensive library of high-affinity small molecules and small molecule fragments of E3 ligases (E3SM), and a Linker system, including a large collection of Bifunctional linker (BF-Linker) with a wide diversity. Those compound libraries help to quickly and efficiently synthesize a large number of high-activity PROTAC bi-specific small molecules, thus greatly accelerating the process of drug R&D.
Medicilon will make every effort to establish and complete its PROTAC biological screening and testing platform, and the follow-up development of preclinical stages.

#BioSeed #Drug Discovery #Chemistry Research #PROTAC